Major US Expert Group to Vote on Altering Baby Hepatitis B Vaccine Recommendation
Following a postponement and a particularly heated gathering, a national immunization advisory committee was scheduled to decide on Friday concerning altering the long-held guideline that each baby be immunized against hepatitis B.
Intense Discussion and a Deferred Vote
The initial day of the meeting on Thursday was defined by heated debate over curbing eligibility to the hepatitis B vaccine for infants and a choice to postpone the decision by a day to provide committee members extra time to examine the language. The panel, which guides the Centers for Disease Control and Prevention on vaccine use, had previously delayed on two occasions.
“Is there any definitive data of harm of giving this immunization before 30 days? Or is this speculation?” questioned one committee member.
In response, another participant stated, “There is scant proof about the enduring danger.”
Present Protocol and Likely Ramifications
The vaccine is currently suggested for every newborn within 24 hours of being born to stop transmission of hepatitis B, which can cause serious liver damage. It has been given to over a billion individuals for over thirty years.
The meeting in Atlanta offered no new evidence of injuries resulting from the vaccine. Authorities state any modification to the current hepatitis B vaccination schedule could have significant and far-reaching consequences for pediatric well-being in the United States.
Group Membership and New Appointments
The advisory panel can only make recommendations to the director of the CDC. The group's roster has undergone changes in recent days, with the announcement that the panel's latest chairman would step down for an official role and be succeeded by a cardiac doctor who has been skeptical about other inoculations.
The board includes a number of vaccination critics who support a goal to reform – and possibly, in some cases, scrap – long-established vaccination recommendations.